OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.19.
A number of research firms have commented on OPRX. Barclays cut their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, November 14th. B. Riley reduced their price objective on OptimizeRx from $17.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, December 24th. Stifel Nicolaus dropped their target price on OptimizeRx from $13.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, November 14th. Stephens began coverage on OptimizeRx in a report on Friday, December 20th. They set an "equal weight" rating and a $5.50 price target on the stock. Finally, Royal Bank of Canada dropped their price objective on shares of OptimizeRx from $14.00 to $7.00 and set an "outperform" rating for the company in a report on Thursday, November 14th.
View Our Latest Report on OPRX
In other news, CEO William J. Febbo bought 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, with a total value of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after buying an additional 2,414 shares during the period. Quest Partners LLC increased its position in shares of OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after acquiring an additional 9,739 shares during the period. Connors Investor Services Inc. increased its position in shares of OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company's stock worth $191,000 after acquiring an additional 2,500 shares during the period. Barclays PLC raised its stake in shares of OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after acquiring an additional 21,060 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in OptimizeRx in the second quarter valued at $282,000. Institutional investors and hedge funds own 76.47% of the company's stock.
Shares of NASDAQ OPRX opened at $5.21 on Friday. The firm has a 50-day simple moving average of $5.15 and a 200-day simple moving average of $7.43. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $95.97 million, a price-to-earnings ratio of -3.92 and a beta of 1.34. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65.
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.